Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 8/20 | 0.48 |
| ▸ | HTR6 | P50406 | 3/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494468 | 0.92 | PRKCZ (0.48) | PRKCZHTR6ROCK1CHRNB2CHRNA4 | |
| SCHEMBL6493661 | 0.81 | MEN1 (0.59) | PRKCZHTR6ROCK1HTR1A | |
| SCHEMBL6495451 | 0.78 | HTR6 (0.55) | HTR6HTR1ACHRNB2CHRNA4 | |
| SCHEMBL6503478 | 0.77 | HTR6 (0.59) | PRKCZHTR6ROCK1 | |
| SCHEMBL6339458 | 0.75 | LTA4H (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL23734312 | 0.72 | KHK (0.58) | PRKCZROCK1 | |
| SCHEMBL4650016 | 0.72 | PRKCZ (0.49) | PRKCZHTR6ROCK1HTR1AHTR7 | |
| SCHEMBL5637866 | 0.70 | PRKCZ (0.50) | PRKCZROCK1HTR2BCHRNB2CHRNA4 | |
| SCHEMBL5639772 | 0.70 | PRKCZ (0.50) | PRKCZROCK1HTR2BCHRNB2CHRNA4 | |
| SCHEMBL28805323 | 0.69 | KMO (0.47) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065186-A1 | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-03-24 | — | — | US | claimed |
| EP-1385842-A1 | HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030069278-A1 | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-04-10 | — | — | US | claimed |
| WO-2002085892-A1 | HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-10-31 | — | — | WO | claimed |
| US-20050065186-A1 | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-03-24 | — | — | US | disclosed |
| US-6815456-B2 | ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-11-09 | — | — | US | disclosed |
| EP-1385842-A1 | HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030069278-A1 | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-04-10 | — | — | US | disclosed |
| WO-2002085892-A1 | HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065186-A1 | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | PRKCZ 3369/4885HTR6 1/4885ROCK1 4184/4885 |
| US-20030069278-A1 | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | PRKCZ 3391/4885HTR6 1/4885ROCK1 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.